参附注射液辅助治疗非小细胞肺癌血小板抑制

目的观察参附注射液辅助治疗非小细胞肺癌患者的血小板临床缓解情况。方法选取2008年10月-2012年10月沧州市人民医院收治的120例非小细胞肺癌(NSCLC)患者,随机分为治疗组60例(予参附注射液静滴和常规化疗),对照组60例(常规化疗),28d为一个疗程,2个疗程后评价两组血小板抑制状况变化。结果治疗组血小板抑制I～Ⅲ度8例,对照组血小板抑制I～Ⅲ度26例,差异有统计学意义(P>0.05)。结论参附注射液对于改善肿瘤患者化疗后的血小板抑制有较好疗效。

Objective To observe the effect of Shenfu Injection on platelet and immune function in patients with the chemotherapy of non-small cell lungcancer（NSCLC）.Methods 120 NSCLC patients were randomly divided into the trial group with 60 cases and the control group with 60 cases.Patients were treated with the injection combined with chemotherapy in the trial group and cases were used the chemotherapy alone in the control group.The variance of thrombolytic toxic reaction and indices of immunity were evaluated after 2 cycles.Results The Ⅰ～Ⅲ degree thrombolytic toxic reaction in the trial group was lower than that in the control group afterchemotherapy. Conclusion It is useful for Shenfu injection to decrease the degree of platelet and increase the immunity function in patients with chemotherapy of NSCLC.